Maryland Capital Advisors Inc. Sells 65 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Maryland Capital Advisors Inc. decreased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 50.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 65 shares of the biopharmaceutical company’s stock after selling 65 shares during the quarter. Maryland Capital Advisors Inc.’s holdings in Regeneron Pharmaceuticals were worth $46,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Rakuten Securities Inc. raised its stake in Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 19 shares in the last quarter. FSA Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals during the third quarter worth about $26,000. Fairfield Financial Advisors LTD acquired a new position in Regeneron Pharmaceuticals during the third quarter worth about $37,000. Private Wealth Management Group LLC raised its stake in Regeneron Pharmaceuticals by 260.0% during the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 39 shares in the last quarter. Finally, Truvestments Capital LLC acquired a new position in Regeneron Pharmaceuticals during the third quarter worth about $39,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on REGN. Citigroup lowered their target price on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Oppenheimer lowered their price objective on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. Leerink Partners raised Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $762.00 to $834.00 in a research note on Wednesday, February 5th. Canaccord Genuity Group downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. Finally, Canaccord Genuity Group initiated coverage on Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective for the company. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $673.60 on Friday. The stock has a market capitalization of $74.02 billion, a price-to-earnings ratio of 17.60, a PEG ratio of 2.38 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a 52-week low of $642.00 and a 52-week high of $1,211.20. The stock’s 50 day moving average price is $709.01 and its two-hundred day moving average price is $900.22. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 4.73.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the prior year, the business earned $11.86 EPS. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 36.67 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.52%. The ex-dividend date is Thursday, February 20th.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.